Accedi ai contenuti
Registrati »
Accedi ai contenuti
Registrati »
Home2019Maggio

Una selezione dei principali articoli della letteratura nazionale e internazionale per l’aggiornamento in farmacia clinica e gestionale

Background and objectives: In economic evaluations in oncology, adjusted survival should be generated if imbalances in prognostic/predictive factors across treatment arms are present. To date, no formal guidance has been developed regarding how such adjustments should be made. We compared various covariate-adjusted survival modeling approaches, as applied to the ENDEAVOR trial in multiple myeloma that assessed carfilzomib plus dexamethasone (Cd)

Lessons learned: The combination of ofatumumab and bendamustine in elderly patients with diffuse large B-cell lymphoma demonstrated modest efficacy compared with standard of care.The poor response may have been due to patient age and the high rate of treatment discontinuation. Background: This phase II trial evaluated the efficacy of bendamustine and ofatumumab in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who were

Background: With the ever-increasing complexity of cancer treatments, oncology medication patient education is becoming a progressively important component of cancer care. Despite this, cancer patients frequently report that they receive inadequate information and feel that their education needs have not been met. Objective: To explore patients' perspectives of optimal oncology medication education across Nova Scotia. Methods: This was a descriptive survey of

Background: Patients with advanced cancer commonly experience pain and it is least controlled in community settings. Community pharmacists in the UK already offer medicines optimisation consultations although not for this patient group. Objective: To determine whether medicines consultations for patients with advanced cancer pain are feasible and acceptable. SettingCommunity-dwelling patients with advanced cancer pain were recruited from primary, secondary and tertiary care

This paper provides an educational review covering the consideration of costs for cost-effectiveness analysis (CEA), summarising relevant methods and research from the published literature. Cost data are typically generated by applying appropriate unit costs to healthcare resource-use data for patients. Trial-based evaluations and decision analytic modelling represent the two main vehicles for CEA. The costs to consider will depend on the

Background: The majority of patients with chronic lymphocytic leukemia (CLL) are older and have multiple comorbidities, including other cancer diagnoses. These patients are routinely excluded from participation in clinical trials. Objective: In this phase II study, we determined the activity and toxicity of ofatumumab, a fully human anti-CD20 monoclonal antibody, in older patients with CLL, poor performance status and comorbidities. Methods: Treatment-naïve patients

Objectives: To identify perceptions of decision-makers and staff at a local hospital about the pharmacist's role in transitions of care (TOC) programs. Setting: Independent community pharmacy located inside a local community hospital. Practise description: Pharmacy personnel offer a bedside delivery service to hospital patients and have professional relationships with administration Practise innovation: Pharmacy personnel intend to expand the bedside delivery service to a